SCHEMBL2803966

SCHEMBL2803966

O=C(NC1CCCCC1)c1cccc(NC(=O)N2CCc3c(cnc4[nH]ncc34)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 4/20 0.47
NAMPT P43490 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KDR P35968 1/20 0.44
CYP3A4 P08684 1/20 0.42
CYP3A5 P20815 1/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
HTR2B P41595 1/20 0.41
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
ANO1 Q5XXA6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804404 1.00 PAK1 (0.47) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2802248 0.92 PAK1 (0.46) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2487737 0.89 NPC1 (0.49) PAK1NPC1RAB9AKDRSMN1; SMN2
SCHEMBL2802904 0.87 RAB9A (0.46) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2488604 0.87 BRAF (0.52) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2806850 0.87 RAB9A (0.60) PAK1NPC1RAB9AKDRSMN1; SMN2
SCHEMBL2487449 0.84 NPC1 (0.50) PAK1NPC1RAB9AKDRPOLB
SCHEMBL2483703 0.84 NPC1 (0.46) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2487956 0.83 NPC1 (0.48) PAK1NAMPTNPC1RAB9AKDR
SCHEMBL2806251 0.83 EPHX2 (0.47) PAK1NAMPTNPC1RAB9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 PAK1 717/4885NAMPT 212/4885NPC1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.